Business Context and Reporting Period
Teladoc Health, Inc. filed a Form 8-K dated September 24, 2026, reporting a change in executive leadership under Item 5.02. The filing does not contain quarterly or annual financial results.
Executive Leadership Change
- Adam C. Vandervoort, Chief Legal Officer and Secretary, notified the company of his resignation effective November 1, 2026.
- The resignation was made with good reason under Mr. Vandervoort’s executive severance agreement.
- Mr. Vandervoort will provide unpaid advisory services through November 1, 2027, primarily to support the transition of his responsibilities.
- Jonathan Dorfman, currently Senior Vice President, Securities & Corporate Law, will become Chief Legal Officer and Secretary following Mr. Vandervoort’s departure.
Financial Metrics and Capital Position
The filing provides no information on revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material Changes, Outlook, and Risks
The primary disclosed change is the planned transition in the company’s chief legal officer and secretary roles. The filing does not quantify severance obligations or describe other compensation arrangements, contingencies, operational impacts, or changes to business guidance.
Key Facts for Investors to Verify
- Effective date of Mr. Vandervoort’s resignation: November 1, 2026.
- Successor: Jonathan Dorfman, currently Senior Vice President, Securities & Corporate Law.
- Advisory period: through November 1, 2027, without compensation for advisory services.
- Potential severance and other obligations under Mr. Vandervoort’s executive severance agreement are not quantified in the filing.